Estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative (ER+PR-HER2-) breast cancer comprise a special type of breast cancer that constitutes ~10% of all breast cancer patients. ER+PR-HER2- tumor benefits less from endocrine therapy...
More than 10 years have passed since the discovery of the second estrogen receptor, estrogen receptor β (ERβ). It is now evident that ERα is not the only ER in breast cancer cells; in fact, ERβ is expressed in the majority of breast cancers although at lower levels than in the no...
Triple-negative breast cancer (TNBC) is the subtype of breast cancer that does not express the estrogen receptor or progesterone receptor and does not overexpress human epidermal growth factor 2. Of all breast cancer subtypes, it carries the worst prognosis and has limited treatment options. Metabol...
Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981;47:554-560.Samaan NA, Buzlar AV, Aldinger KA et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981; 47554-560.Samaan NA, Buzdar AU, Aldinger KA et al (1981) Estrogen receptor: a prognostic ...
5. Yuan P, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019;112:57–65. 6. Jerusalem G, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Posi...
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfor...
近日,医学期刊NPJ breast Cancer在线发表了具有地域及人种多样性的多中心真实世界研究(P-REALITY X)的分析结果 。研究表明CDK4/6抑制剂联合AI治疗可改善HR+/HER2- 转移性乳腺癌患者的总生存(OS)及真实世界无进展生存(rwPFS)。研究数...
标题:Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC) 报告人:Matthew P. Goetz (Rochester, United States of America) ...
[10] Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. ASCO 2022 ...
estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer donald a. berry, phd ; constance cirrincione, ms ; i. craig henderson, md ; et al marc l. citron, md ; daniel r. budman, md ; lori j. goldstein, md ; silvana martino, do ; ...